Drug intelligence / Profile preview

RapVac-2301

Development stage: Preclinical
Lead developer: RAPHAS
Modality: Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

RapVac-2301 is a preclinical-stage quadrivalent influenza vaccine (QIV) developed by RAPHAS. It utilizes a microneedle patch delivery system to administer cell-based influenza hemagglutinin (HA) antigens targeting four strains: A/H1, A/H3, B/Yamagata, and B/Victoria. The vaccine is designed to induce immune responses against seasonal influenza through intradermal delivery, which potentially offers improved stability and ease of administration compared to traditional intramuscular injections. RAPHAS aims for IND approval for this candidate in 2027.

Other names: QIV influenza vaccine

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on RapVac-2301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RapVac-2301.

Explore the full profile